TitleProjected Impact of Mexico's Sugar-Sweetened Beverage Tax Policy on Diabetes and Cardiovascular Disease: A Modeling Study.
Publication TypeJournal Article
Year of Publication2016
AuthorsSánchez-Romero, LMaria, Penko, J, Coxson, PG, Fernández, A, Mason, A, Moran, AE, Ávila-Burgos, L, Odden, MC, Barquera, S, Bibbins-Domingo, K
JournalPLoS Med
Volume13
Issue11
Paginatione1002158
Date Published2016 Nov
ISSN1549-1676
KeywordsAdult, Aged, Aged, 80 and over, Beverages, Cardiovascular Diseases, Computer Simulation, Diabetes Mellitus, Type 2, Dietary Sucrose, Female, Health Care Costs, Humans, Incidence, Male, Mexico, Middle Aged, Models, Theoretical, Prevalence, Risk Factors, Sweetening Agents, Taxes
Abstract
 

BACKGROUND: Rates of diabetes in Mexico are among the highest worldwide. In 2014, Mexico instituted a nationwide tax on sugar-sweetened beverages (SSBs) in order to reduce the high level of SSB consumption, a preventable cause of diabetes and cardiovascular disease (CVD). We used an established computer simulation model of CVD and country-specific data on demographics, epidemiology, SSB consumption, and short-term changes in consumption following the SSB tax in order to project potential long-range health and economic impacts of SSB taxation in Mexico.

METHODS AND FINDINGS: We used the Cardiovascular Disease Policy Model-Mexico, a state transition model of Mexican adults aged 35-94 y, to project the potential future effects of reduced SSB intake on diabetes incidence, CVD events, direct diabetes healthcare costs, and mortality over 10 y. Model inputs included short-term changes in SSB consumption in response to taxation (price elasticity) and data from government and market research surveys and public healthcare institutions. Two main scenarios were modeled: a 10% reduction in SSB consumption (corresponding to the reduction observed after tax implementation) and a 20% reduction in SSB consumption (possible with increases in taxation levels and/or additional measures to curb consumption). Given uncertainty about the degree to which Mexicans will replace calories from SSBs with calories from other sources, we evaluated a range of values for calorie compensation. We projected that a 10% reduction in SSB consumption with 39% calorie compensation among Mexican adults would result in about 189,300 (95% uncertainty interval [UI] 155,400-218,100) fewer incident type 2 diabetes cases, 20,400 fewer incident strokes and myocardial infarctions, and 18,900 fewer deaths occurring from 2013 to 2022. This scenario predicts that the SSB tax could save Mexico 983 million international dollars (95% UI $769 million-$1,173 million). The largest relative and absolute reductions in diabetes and CVD events occurred in the youngest age group modeled (35-44 y). This study's strengths include the use of an established mathematical model of CVD and use of contemporary Mexican vital statistics, data from health surveys, healthcare costs, and SSB price elasticity estimates as well as probabilistic and deterministic sensitivity analyses to account for uncertainty. The limitations of the study include reliance on US-based studies for certain inputs where Mexico-specific data were lacking (specifically the associations between risk factors and CVD outcomes [from the Framingham Heart Study] and SSB calorie compensation assumptions), limited data on healthcare costs other than those related to diabetes, and lack of information on long-term SSB price elasticity that is specific to geographic and economic subgroups.

CONCLUSIONS: Mexico's high diabetes prevalence represents a public health crisis. While the long-term impact of Mexico's SSB tax is not yet known, these projections, based on observed consumption reductions, suggest that Mexico's SSB tax may substantially decrease morbidity and mortality from diabetes and CVD while reducing healthcare costs.

DOI10.1371/journal.pmed.1002158
Alternate JournalPLoS Med.
PubMed ID27802278
PubMed Central IDPMC5089730
Grant ListK01 AG039387 / AG / NIA NIH HHS / United States
K24 DK102057 / DK / NIDDK NIH HHS / United States
R03 TW009061 / TW / FIC NIH HHS / United States